Abstract
Short synthetic small-hairpin RNAS (sshRNAs) (SG220 and SG273) that target the internal ribosome entry site of the hepatitis C virus (HCV) were formulated into lipid nano-particles and administered intravenously to HCV-infected urokinase plasminogen activator–severe combined immunodeficient mice with livers repopulated with human hepatocytes (humanized livers). Weekly administration of 2.5 mg/kg of each sshRNA for 2 weeks resulted in a maximal mean reduction in viral load of 2.5 log10 from baseline. The viral load remained reduced by more than 90% at 14 days after the last dose was given. The sshRNAs were well tolerated and did not significantly increase liver enzyme levels. These findings indicate the in vivo efficacy of a synthetic RNA inhibitor against the HCV genome in reducing HCV infection.
Keywords: Short shRNA, uPA-SCID Chimeric Mice, RNA Interference, siRNA, HCV
Hepatitis C virus (HCV) infection is a leading cause of chronic liver diseases including cirrhosis and hepatocellular carcinoma.1 The vast number of HCV quasispecies present in any infected individual results in a high potential for developing resistance to direct-acting antiviral agents, which can lead to treatment failure.2,3 Thus, most investigational new treatments of chronic HCV infection use a combination of molecules with complementary mechanisms and nonoverlapping resistance profiles. RNA interference (RNAi) potentially offers such a therapeutic approach by directly targeting multiple sites on viral RNA. Here, we report the potent, durable, and specific inhibition of HCV infection in vivo by 2 short synthetic hairpin RNAs (sshRNAs) formulated with lipid nanoparticles (LNPs).4
The sshRNAs (SG220 and SG273), whose in vitro activity was characterized previously,5,6 target a conserved region within the internal ribosome entry site (IRES) of the HCV genome (Supplementary Figure 1A) with perfect target complementarity to genotypes 1a, 1b, 4a, and 5a, a single mismatch to genotype 2a,7 and more than one mismatch to genotypes 3 and 6. sshRNAs induce RNAi by a noncanonical mechanism in which intact hairpins are loaded into RISC and are activated by Ago2-mediated slicer processing of the passenger arm without Dicer cleavage.8 sshRNAs also differ from siRNAs in consisting of a single molecular entity and having a loop that hinders off-target activity by the passenger strand.8 Both sshRNAs induced potent knockdown of IRES-directed firefly luciferase reporter gene activity in HEK-293FT cells without significant in vitro or in vivo immune-stimulatory activity,5,9 and LNP-formulated SG220 was shown to effect prolonged knockdown in an HCV IRES-dependent bioluminescence mouse model.9,10
Chimeric urokinase-type plasminogen activator-severe combined immunodeficiency (uPA-SCID) mice with human hepatocyte reconstitution have been used previously to show the antiviral potency of various HCV inhibitors known to be effective in HCV-infected patients.11–13 To test sshRNAs in this model, we first examined the uptake of the LNP-formulated sshRNA SG220 in chimeric uPA-SCID mice and compared it with that of regular SCID mice. Results obtained from 3 chimeric and 3 regular SCID mice showed similar levels of sshRNA in the livers of the chimeric and regular SCID mice, as determined by a ribonuclease protection assay (RPA) (Figure 1, lanes 4–6 and 8–10). The specificity of the RPA for SG220 was shown by the lack of protection of the probe by total liver RNA from the phosphate-buffered saline (PBS)-treated mice (Figure 1, lane 2). By comparing the band intensities of the protected probe with those of SG220 standards (Figure 1, lanes 11–14), it was determined that 5.9% ± 1.4% (mean ± SD) of the total injected SG220 remained in the chimeric mouse liver 48 hours after treatment, compared with 5.1% ± 0.7% in the SCID mouse liver (Supplementary Table 1). The presence of abundant sshRNA in the liver 48 hours after treatment suggests that the human hepatocytes in the chimeric mouse liver can efficiently take-up LNP-formulated sshRNA and that significant amounts remain intact. This is consistent with previous reports in which LNPs designed for efficient delivery to liver have been shown to accumulate 70%–80% of the total injected dose in the liver of mice within the first 24 hours after intravenous administration14 and to be readily taken up by hepatocytes by virtue of receptor-mediated endocytosis mediated by the in vivo adoption of endogenous apolipoprotein E, a ligand for the low-density lipoprotein–receptor family of cell surface receptors.15
We next assessed the activity of the 2 sshRNAs against HCV replication in chimeric uPA-SCID mice that had high proportions of human hepatocytes (serum human albumin level, ≥8 mg/mL in all mice) and were stably infected with genotype 1a HCV (serum HCV-RNA level, ≥4.0 ± 106 IU/mL in all mice) (Supplementary Table 2). Four mice in each group received 2 intravenous injections, given 1 week apart, of LNP-formulated SG220, SG273, a combination of SG220 and SG273, or an irrelevant (scrambled) sshRNA at 2.5 or 5.0 mg/kg (Figure 2A and B). Serum HCV viral titer was monitored twice every week. All mice receiving HCV-specific sshRNAs had more than a 90% (1 log10) reduction in serum HCV-RNA concentration after a single dose. Treatment with 2.5 mg/kg SG220 or SG273 led to a 1.8 log10 or 1.2 log10 mean reduction in HCV-RNA concentration, respectively, at 72 hours after the first injection (P < .01; Figure 2A and B). A higher dose of SG220 (5 mg/kg) did not lead to a further reduction in viral load (Figure 2A). The combination of 2.5 mg/kg SG220 and 2.5 mg/kg SG273 provided the strongest inhibition of HCV replication, with a 2 log10 reduction in HCV-RNA concentration observed 72 hours after the first dose and an additional 0.5 log10 reduction 7 days after the second dose (P < .01; Figure 3B). The inhibition of HCV replication by HCV sshRNA was specific because the serum HCV viral load in mice treated with the LNP-formulated irrelevant control sshRNA at 5 mg/kg did not change significantly at any time point during the study.
The mean viral load reduction in all HCV sshRNA-treated groups was durable. In mice treated with either 2.5 mg/kg SG220 or the combination of SG220 and SG273, the HCV serum viral load remained significantly lower (P < .01) than the pretreatment level, up to the last study time point 3 weeks after the second and last doses (Supplementary Table 3). In the case of 2 mice whose pretreatment HCV serum RNA levels were less than 107, viral load remained 1.5 and 2.6 log10 below pretreatment levels at 3 weeks after treatment (Supplementary Figure 2). In the mice treated with SG273 alone, the HCV serum viral load remained significantly lower relative to the pretreatment level up to 2 weeks after the second dose (P < .05) (Figure 2B, Supplementary Table 3).
LNP-formulated sshRNAs were well tolerated. There was no treatment-related increase of liver alanine aminotransferase or aspartate aminotransferase levels in any of the treatment groups or a reduction in serum human albumin concentration (Figure 2C), indicating the absence of significant hepatocyte toxicity during the dosing and follow-up periods. There was also no treatment-associated body weight loss and no observations of morbidity or mortality in the study animals. These results, together with the lack of antiviral effect of the irrelevant sshRNAs, suggest that the reduction of serum HCV-RNA concentration by the HCV-targeting sshRNAs was specific.
There have been reports of RNAi-mediated inhibition of HCV in HCV subgenomic replicon systems and cell culture–based infectious HCV systems.16–18 However, it is not known if RNAi can achieve clinically significant levels of antiviral efficacy against chronic HCV infection in vivo. Our results show that the LNP-formulated4 HCV targeting sshRNAs efficiently inhibit HCV replication in the uPA-SCID chimeric mice, a model that supports high levels of HCV replication. The RNAi effect of LNP-formulated sshRNA treatment was long-lasting, suggesting that such agents could be effective even with infrequent dosing. The fact that SG220 showed higher potency than SG273 both in vitro and in vivo is consistent with a direct-acting antiviral mechanism of action.5,6,8 This study reports inhibition of HCV virus replication by synthetic RNAs through an RNAi mechanism in a robust HCV infection model, and adds HCV to the small group of viruses shown to be targetable with RNAi.19
Supplementary Material
Acknowledgments
The authors thank Palanikumar Ravindran for statistical analysis, Suryanarayana Sankuratri for management of the collaboration, Sergei A. Kazakov for advice in development of the short synthetic hairpin RNA detection assay, and Yoshio Morikawa and colleagues at PhoenixBio, Inc, for conducting the studies in the chimeric mice and hepatitis C virus–RNA titer determination.
Brian Johnston, Han Ma, Anne Dallas, Ian MacLachlan, Heini Ilves, and Klaus Klumpp designed the study; Anne Dallas, Heini Ilves, and Joshua Shorenstein performed the research; Ian MacLachlan provided lipid nanoparticle formulation of short synthetic hairpin RNAs; Han Ma, Anne Dallas, Brian Johnston, Klaus Klumpp, and Heini Ilves analyzed and interpreted the data; and Han Ma, Brian Johnston, Anne Dallas, and Klaus Klumpp wrote the manuscript.
Funding
Supported by National Institutes of Health grants R44AI056611, R44AI074256, and R43AI074214 (B.H.J.).
Abbreviations used in this paper
- HCV
hepatitis C virus
- IRES
internal ribosome entry site
- LNP
lipid nanoparticle
- PBS
phosphate-buffered saline
- RNAi
RNA interference
- RPA
ribonuclease protection assay
- sshRNA
short synthetic hairpin RNA
- uPA-SCID
urokinase-type plasminogen activator-severe combined immunodeficiency
Footnotes
Note: To access the supplementary material accompanying this article, visit the online version of Gastroenterology at www.gastrojournal.org, and at http://dx.doi.org/10.1053/j.gastro.2013.09.049.
Author names in bold designate shared co-first authorship.
Conflicts of interest
The authors disclose the following: Han Ma and Klaus Klumpp are employees of Hoffmann-La Roche, Inc; Brian Johnston, Anne Dallas, Heini Ilves, and Joshua Shorenstein are employees of SomaGenics, Inc; and Ian MacLachlan is an employee of Tekmira Pharmaceuticals.
References
- 1.Perz JF, et al. J Hepatol. 2006;45:529–538. doi: 10.1016/j.jhep.2006.05.013. [DOI] [PubMed] [Google Scholar]
- 2.Martell M, et al. J Virol. 1992;66:3225–3229. doi: 10.1128/jvi.66.5.3225-3229.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Sun JH, et al. Hepatology. 2012;55:1692–1699. doi: 10.1002/hep.25581. [DOI] [PubMed] [Google Scholar]
- 4.Jeffs LB, et al. Pharm Res. 2005;22:362–372. doi: 10.1007/s11095-004-1873-z. [DOI] [PubMed] [Google Scholar]
- 5.Ge Q, et al. RNA. 2010;16:118–130. doi: 10.1261/rna.1901810. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Ge Q, et al. RNA. 2010;16:106–117. doi: 10.1261/rna.1894510. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Kronke J, et al. J Virol. 2004;78:3436–3446. doi: 10.1128/JVI.78.7.3436-3446.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Dallas A, et al. Nucleic Acids Res. 2012;40:9255–9271. doi: 10.1093/nar/gks662. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Dallas A, Ilves H, et al. Mol Ther Nucleic Acids. 2013 doi: 10.1038/mtna.2013.50. In press. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Kolli S, et al. Bioconjug Chem. 2013;24:314–332. doi: 10.1021/bc3004099. [DOI] [PubMed] [Google Scholar]
- 11.Kamiya N, et al. J Gen Virol. 2010;91:1668–1677. doi: 10.1099/vir.0.019315-0. [DOI] [PubMed] [Google Scholar]
- 12.Shi N, et al. Gut. 2013;62:1055–1061. doi: 10.1136/gutjnl-2012-302600. [DOI] [PubMed] [Google Scholar]
- 13.Meuleman P, et al. Antiviral Res. 2008;80:231–238. doi: 10.1016/j.antiviral.2008.07.006. [DOI] [PubMed] [Google Scholar]
- 14.MacLachlan I. Liposomal formulations for nucleic acid delivery. In: Crooke ST, editor. Antisense drug technology: principles, strategies, and applications. 2. CRC Press; 2007. pp. 237–270. [Google Scholar]
- 15.Akinc A, et al. Mol Ther. 2010;18:1357–1364. doi: 10.1038/mt.2010.85. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Kanda T, et al. J Virol. 2007;81:669–676. doi: 10.1128/JVI.01496-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Wilson JA, et al. J Virol. 2005;79:7050–7058. doi: 10.1128/JVI.79.11.7050-7058.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Yokota T, Sakamoto N, et al. EMBO Rep. 2003;4:602–608. doi: 10.1038/sj.embor.embor840. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Shah PS, et al. Pharm Res. 2011;28:2966–2982. doi: 10.1007/s11095-011-0549-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.